This article has been updated from a previous version to include comments from Seryx.
Researchers from Johns Hopkins University's Genetics and Public Policy Center last week said they uncovered inconsistencies and misleading claims made by companies selling CYP450 testing services designed to help guide treatments of certain antidepressants.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.